Search

Your search keyword '"Bergauer, Tobias"' showing total 18 results
Start Over Author "Bergauer, Tobias"
18 results on '"Bergauer, Tobias"'

1. Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics

Author

Valdeolivas, Alberto, Amberg, Bettina, Giroud, Nicolas, Richardson, Marion, Gálvez, Eric J. C., Badillo, Solveig, Julien-Laferrière, Alice, Túrós, Demeter, Voith von Voithenberg, Lena, Wells, Isabelle, Pesti, Benedek, Lo, Amy A., Yángüez, Emilio, Das Thakur, Meghna, Bscheider, Michael, Sultan, Marc, Kumpesa, Nadine, Jacobsen, Björn, Bergauer, Tobias, Saez-Rodriguez, Julio, Rottenberg, Sven, Schwalie, Petra C., and Hahn, Kerstin

Published
2024
Full Text
View/download PDF

2. Charting the Heterogeneity of Colorectal Cancer Consensus Molecular Subtypes using Spatial Transcriptomics

Author

Valdeolivas, Alberto, primary, Amberg, Bettina, additional, Giroud, Nicolas, additional, Richardson, Marion, additional, Gálvez, Eric J.C., additional, Badillo, Solveig, additional, Julien-Laferrière, Alice, additional, Turos, Demeter, additional, von Voithenberg, Lena Voith, additional, Wells, Isabelle, additional, Lo, Amy A., additional, Yángüez, Emilio, additional, Das Thakur, Meghna, additional, Bscheider, Michael, additional, Sultan, Marc, additional, Kumpesa, Nadine, additional, Jacobsen, Björn, additional, Bergauer, Tobias, additional, Saez-Rodriguez, Julio, additional, Rottenberg, Sven, additional, Schwalie, Petra C., additional, and Hahn, Kerstin, additional

Published
2023
Full Text
View/download PDF

3. Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime

Author

Moll, Solange, Yasui, Yukari, Abed, Ahmed, Murata, Takeshi, Shimada, Hideaki, Maeda, Akira, Fukushima, Naoshi, Kanamori, Masakazu, Uhles, Sabine, Badi, Laura, Cagarelli, Thomas, Formentini, Ivan, Drawnel, Faye, Georges, Guy, Bergauer, Tobias, Gasser, Rodolfo, Bonfil, R. Daniel, Fridman, Rafael, Richter, Hans, Funk, Juergen, Moeller, Marcus J., Chatziantoniou, Christos, and Prunotto, Marco

Published
2018
Full Text
View/download PDF

7. MOESM1 of Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime

Author

Moll, Solange, Yasui, Yukari, Abed, Ahmed, Murata, Takeshi, Shimada, Hideaki, Maeda, Akira, Naoshi Fukushima, Kanamori, Masakazu, Uhles, Sabine, Badi, Laura, Cagarelli, Thomas, Formentini, Ivan, Drawnel, Faye, Georges, Guy, Bergauer, Tobias, Gasser, Rodolfo, R. Bonfil, Fridman, Rafael, Richter, Hans, Juergen Funk, Moeller, Marcus, Chatziantoniou, Christos, and Prunotto, Marco

Subjects
Data_FILES
Abstract

Additional file 1. Additional figures.

Published
2018
Full Text
View/download PDF

8. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

Author

Sturm, Stefan, primary, Günther, Andreas, additional, Jaber, Birgit, additional, Jordan, Paul, additional, Al Kotbi, Nada, additional, Parkar, Nikhat, additional, Cleary, Yumi, additional, Frances, Nicolas, additional, Bergauer, Tobias, additional, Heinig, Katja, additional, Kletzl, Heidemarie, additional, Marquet, Anne, additional, Ratni, Hasane, additional, Poirier, Agnès, additional, Müller, Lutz, additional, Czech, Christian, additional, and Khwaja, Omar, additional

Published
2018
Full Text
View/download PDF

9. Longitudinal characterization of biomarkers for spinal muscular atrophy

Author

Bonati, Ulrike, primary, Holiga, Štefan, additional, Hellbach, Nicole, additional, Risterucci, Céline, additional, Bergauer, Tobias, additional, Tang, Wakana, additional, Hafner, Patricia, additional, Thoeni, Alain, additional, Bieri, Oliver, additional, Gerlach, Irene, additional, Marquet, Anne, additional, Khwaja, Omar, additional, Sambataro, Fabio, additional, Bertolino, Alessandro, additional, Dukart, Juergen, additional, Fischmann, Arne, additional, Fischer, Dirk, additional, and Czech, Christian, additional

Published
2017
Full Text
View/download PDF

10. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.

Author

Sturm, Stefan, Günther, Andreas, Jaber, Birgit, Jordan, Paul, Al Kotbi, Nada, Parkar, Nikhat, Cleary, Yumi, Frances, Nicolas, Bergauer, Tobias, Heinig, Katja, Kletzl, Heidemarie, Marquet, Anne, Ratni, Hasane, Poirier, Agnès, Müller, Lutz, Czech, Christian, and Khwaja, Omar

Subjects
MOTOR neuron diseases, CLINICAL trials, MESSENGER RNA, NEURODEGENERATION, PHARMACOKINETICS
Abstract

Aims: Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy (SMA). The objectives of this entry‐into‐human study were to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of risdiplam, and the effect of the strong CYP3A inhibitor itraconazole on the PK of risdiplam in healthy male volunteers. Methods: Part 1 had a randomized, double‐blind, adaptive design with 25 subjects receiving single ascending oral doses of risdiplam (ranging from 0.6–18.0 mg, n = 18) or placebo (n = 7). A Bayesian framework was applied to estimate risdiplam's effect on SMN2 mRNA. The effect of multiple doses of itraconazole on the PK of risdiplam was also assessed using a two‐period cross‐over design (n = 8). Results: Risdiplam in the fasted or fed state was well tolerated. Risdiplam exhibited linear PK over the dose range with a multi‐phasic decline with a mean terminal half‐life of 40–69 h. Food had no relevant effect, and itraconazole had only a minor effect on plasma PK indicating a low fraction of risdiplam metabolized by CYP3A. The highest tested dose of 18.0 mg risdiplam led to approximately 41% (95% confidence interval 27–55%) of the estimated maximum increase in SMN2 mRNA. Conclusions: Risdiplam was well tolerated and proof of mechanism was demonstrated by the intended shift in SMN2 splicing towards full‐length SMN2 mRNA. Based on these data, Phase 2/3 studies of risdiplam in patients with SMA are now ongoing. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

11. Optimized solutions for RNAi experiments

Author

Scanlan, Elizabeth, Dennig, Jorg, Kruger, Ute, Bergauer, Tobias, Magyar, Silvia, and Lader, Eric

Subjects
Gene silencing -- Analysis, Biotechnology industry, Business
Abstract

The advantages of using double-stranded short interfering RNAs, as a method to achieve targeted gene silencing, are presented.

Published
2005

12. HepG2/C3A 3D spheroids exhibit stable physiological functionality for at least 24 days after recovering from trypsinisation

Author

Wrzesinski, Krzysztof, primary, Magnone, Maria Chiara, additional, Hansen, Line Visby, additional, Kruse, Marianne Ehrhorn, additional, Bergauer, Tobias, additional, Bobadilla, Maria, additional, Gubler, Marcel, additional, Mizrahi, Jacques, additional, Zhang, Kelan, additional, Andreasen, Christina M., additional, Joensen, Kira Eyð, additional, Andersen, Signe Marie, additional, Olesen, Jacob Bastholm, additional, Schaffalitzky de Muckadell, Ove B., additional, and Fey, Stephen J., additional

Published
2013
Full Text
View/download PDF

13. Expression Profiling of Human Immune Cell Subsets Identifies miRNA-mRNA Regulatory Relationships Correlated with Cell Type Specific Expression

Author

Allantaz, Florence, primary, Cheng, Donavan T., additional, Bergauer, Tobias, additional, Ravindran, Palanikumar, additional, Rossier, Michel F., additional, Ebeling, Martin, additional, Badi, Laura, additional, Reis, Bernhard, additional, Bitter, Hans, additional, D'Asaro, Matilde, additional, Chiappe, Alberto, additional, Sridhar, Sriram, additional, Pacheco, Gonzalo Duran, additional, Burczynski, Michael E., additional, Hochstrasser, Denis, additional, Vonderscher, Jacky, additional, and Matthes, Thomas, additional

Published
2012
Full Text
View/download PDF

17. HepG2/C3A 3D spheroids exhibit stable physiological functionality for at least 24 days after recovering from trypsinisation.

Author

Krzysztof Wrzesinski, Magnone, Maria Chiara, Hansen, Line Visby, Kruse, Marianne Ehrhorn, Bergauer, Tobias, Bobadill, Maria, Gubler, Marcel, Mizrahi, Jacques, Kelan Zhang, Andreasen, Christina M., Joensen, Kira Eyð, Andersen, Signe Marie, Olesen, Jacob Bastholm, and de Muckadell, Ove B. Schaffalitzky

Abstract

Primary human hepatocytes are widely used as an in vitro system for the assessment of drug metabolism and toxicity. Nevertheless a cell system with higher stability of physiological functions is required for the investigation of drugs’ mode of action, pathway analyses and biomarkers evaluations. We recently discovered that the human hepatocellular carcinoma cell line, HepG2/C3A, cultured as spheroids in a 3D system can recover their main functions after trypsinisation within about 18 days. The objective of this study was to investigate whether the spheroids’ metabolic functions remained stable after this recovery period. Therefore we evaluated physiological capabilities of the spheroids (cell survival, growth rate, glycogenesis, ATP, cholesterol and urea synthesis and drug metabolism) and the expression of key genes related to the main liver pathways in spheroids cultured for an additional 24 days after full recovery (day 18). Here we show that after the recovery period, the 3D spheroid culture can provide a metabolically competent homeostatic cell model which is in equilibrium with its culture environment for more than 3 weeks. Such a stable system could be used for the assessment of the drugs’ mode of action, for biomarkers evaluation and for any systems biology studies which require medium- to long-term stability of metabolic functions [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

18. HepG2/C3A 3D spheroids exhibit stable physiological functionality for at least 24 days after recovering from trypsinisation

Author

WrzesinskiThese authors equally contributed to the study., Krzysztof, Magnone, Maria Chiara, Hansen, Line Visby, Kruse, Marianne Ehrhorn, Bergauer, Tobias, Bobadilla, Maria, Gubler, Marcel, Mizrahi, Jacques, Zhang, Kelan, Andreasen, Christina M., Joensen, Kira Eyð, Andersen, Signe Marie, Olesen, Jacob Bastholm, Schaffalitzky de Muckadell, Ove B., and Fey, Stephen J.

Abstract

Primary human hepatocytes are widely used as an in vitrosystem for the assessment of drug metabolism and toxicity. Nevertheless a cell system with higher stability of physiological functions is required for the investigation of drugs’ mode of action, pathway analyses and biomarkers evaluations. We recently discovered that the human hepatocellular carcinoma cell line, HepG2/C3A, cultured as spheroids in a 3D system can recover their main functions after trypsinisation within about 18 days. The objective of this study was to investigate whether the spheroids’ metabolic functions remained stable after this recovery period. Therefore we evaluated physiological capabilities of the spheroids (cell survival, growth rate, glycogenesis, ATP, cholesterol and urea synthesis and drug metabolism) and the expression of key genes related to the main liver pathways in spheroids cultured for an additional 24 days after full recovery (day 18). Here we show that after the recovery period, the 3D spheroid culture can provide a metabolically competent homeostatic cell model which is in equilibrium with its culture environment for more than 3 weeks. Such a stable system could be used for the assessment of the drugs’ mode of action, for biomarkers evaluation and for any systems biology studies which require medium- to long-term stability of metabolic functions.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results